tumor protein p53 inducible nuclear protein 2Genealiases: C20orf110 · DOR · PINH · dJ1181N3.1
Q-omics provides the consensus-scored TP53INP2 profile across patient tissues and cancer cell-line models. TP53INP2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TP53INP2 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, TP53INP2 RNA expression shows 19,589 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, BLCA, and THYM as cancer lineages where TP53INP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TP53INP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TP53INP2 survival associations across molecular data types. TP53INP2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TP53INP2 RNA expression–survival associations across cancer types. High TP53INP2 expression shows unfavorable associations in BLCA, UVM and LUAD, but favorable associations in KIRC, SCLC and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TP53INP2 RNA expression.
This table summarizes TP53INP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for TP53INP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TP53INP2 shows lower tumor expression in BLCA, COAD, THCA, KIRP, HNSC and READ. The BLCA box plot shows higher TP53INP2 RNA expression in normal versus tumor tissue (log2 FC = −2.847, t-test p < 0.001).
This table shows molecular features associated with TP53INP2 in patient tissues and cancer cell lines. In patient samples, TP53INP2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TP53INP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BONE.
